Chemomab Therapeutics Announces Publication in JCI Insight Demonstrating Key Role of CCL24 in Primary Sclerosing Cholangitis
--Includes Extensive Data Showing that CM-101, Chemomab's CCL24-Neutralizing Antibody, Interrupts the Fibro-Inflammatory Processes that Lead to PSC-- TEL AVIV, Israel, June 28, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), ...
Source: marketscreener.com